发明名称 LANTHIONINE SYNTHETASE C-LIKE 2-BASED THERAPEUTICS
摘要 Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.
申请公布号 US2016115153(A1) 申请公布日期 2016.04.28
申请号 US201514662506 申请日期 2015.03.19
申请人 Biotherapeutics, Inc. 发明人 Bassaganya-Riera Josep;Carbo Barrios Adria;Gandour Richard;Cooper Julian D.;Hontecillas Raquel
分类号 C07D401/14;C07D403/14;C07D213/79;C07D413/12;C07D307/68;C07C65/40;C07D413/14;C07D403/12 主分类号 C07D401/14
代理机构 代理人
主权项 1. A compound comprising formula Z-Y-Q-Y′-Z′ or a pharmaceutically acceptable salt or ester thereof, wherein: Z is: Y is: Q is piperazine-1,4-diyl; 2,5-diazabicyclo[2.2.1]heptane-2,5-diyl; 2,5-diazabicyclo[2.2.2]octane-2,5-diyl; 1,4-diazepane-1,4-diyl; benzene-1,4-diamine-N1,N4-diyl; ethane-1,2-diamine-N1,N2-diyl; N1,N2-dialkylethane-1,2-diamine-N1,N2-diyl; propane-1,3-diamine-N1,N3-diyl; N1,N3-dialkylpropane-1,3-diamine-N1,N3-diyl; 1,4-diaminoanthracene-9,10-dione-1,4-diyl; C6 arene-1,4-diamine-N1,N4-diyl wherein the arene is substituted with one to four substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of —C(O)O(C1 to C6)alkyl, OH, O(C1 to C6)alkyl, (C1 to C6)alkyl, CF3, F, Cl, and Br; or substituted piperazine-1,4-diyl wherein the piperazine is substituted with one to eight substituents in the 2, 3, 5, or 6 positions and wherein the substituents are independently selected from the group consisting of (C1 to C6)alkyl, aryl, aryl(C1 to C6)alkyl, C(O)OH, and C(O)O(C1 to C6)alkyl; Y′ is:  or a single bond; and Z′ is:or R5; wherein: Y′ is a single bond only when Z′ is R5;A1 and A1′ are each independently N, N(C1 to C6)alkyl, O, S, or CR6;A2 and A2′ are each independently N or CR7;A3 and A3′ are each independently NR8, O, or S;A4 and A4′ are each independently N or CR9;A5 and A5′ are each independently N or CR10;A6 and A6′ are each independently N or CR11;R1, R1″, R2, R3′, R3, R3′, R4, R4′, R5, R6, R7, R8, R9, R10, and R11 are each independently selected from the group consisting of hydrogen; alkyl; halo; trifluoromethyl; dialkylamino wherein each alkyl is independently selected; —NH2; alkylamino; arylalkyl; heteroarylalkyl; heterocycloalkyl; substituted heterocycloalkyl substituted with 1 to 2 substituents independently selected from the group consisting of —C(O)OH, —C(O)O(C1 to C6)alkyl, (C1 to C6)alkyl, —CF3, F, Cl, and Br; and substituted heteroarylalkyl; wherein the substituted heteroarylalkyl is substituted with 1 to 3 substituents independently selected from the group consisting of —NH2; —NH(C1 to C6)alkyl; —N((C1 to C6)alkyl)2 wherein each alkyl is independently selected; alkyl; halo; aryl; substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of —SO2R12, —OR13, -halo, —CN, —CF3, aminoalkyl-, —S(O)R14, and alkyl; heterocycloalkyl; heteroaryl; substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of alkyl, —CF3, F, Cl, and Br; alkylamino-; heterocycloalkyl-alkyl-amino-; alkylaminoalkylamino-; —NHC(O)OR15; —NHC(O)NR16R17; —C(O)NR16R17; and substituted heteroaryl substituted with 1 to 3 substituents selected from the group consisting of alkyl, halo, CN, NH2, —NH(C1-C6 alkyl), —N(C1-C6 alkyl)2 wherein each alkyl is independently selected, —CF3, and substituted aryl substituted with 1 to 3 substituents independently selected from the group consisting of —S(O)2R15 and —CN; wherein R12, R13, R14, R15, R16, and R17 are each independently selected from the group consisting of C1-C6 alkyl, dialkylamino comprising independently selected C1-C6 alkyl, —NH2, alkylamino, heterocycloalkyl, and substituted heterocycloalkyl substituted with one to two substituents independently selected from the group consisting of —C(O)O(C1-C6 alkyl) and C1-C6 alkyl.
地址 Blacksburg VA US